Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2024 report and make more profitable business decisions.
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen, and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary Biliary Cholangitis (Primary Biliary Cirrhosis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 35 molecules, with 35 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary Biliary Cholangitis (Primary Biliary Cirrhosis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary Biliary Cholangitis (Primary Biliary Cirrhosis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4P-Pharma SASAscletis Pharma Inc
Avolynt Inc
Brillian Pharma Inc.
Calliditas Therapeutics AB
CAMP4 Therapeutics Corp
Cascade Pharmaceuticals Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cour Pharmaceuticals Development Co Inc
CymaBay Therapeutics Inc
Diapin Therapeutics LLC
Dr. Falk Pharma GmbH
Future Medicine Co Ltd
GentiBio Inc
Guangdong Raynovent Biotech Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Intercept Pharmaceuticals Inc
Invea Therapeutics Inc
Ipsen SA
Kowa Co Ltd
MediGene AG
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Ohara Pharmaceutical Co Ltd
Parvus Therapeutics Inc
Shaanxi Micot Technology Co Ltd
Shanghai Henlius Biotech Inc
Sihuan Pharmaceutical Holdings Group Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Umecrine Cognition AB
Xiamen Boruilai Pharmaceutical Technology Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions